



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
VICTOR MINYON BUILDING, 1500 PENNSYLVANIA AVENUE, N.W.  
WASHINGTON, D.C. 20540  
www.uspto.gov

APPLICATION NO	FILING DATE	FIRST NAME INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO
09 745,226	12 21 2000	Robert A. Hermann	40109	7530

27774 7590 02 25 2003

MAYER, FORTKORT & WILLIAMS, PC  
251 NORTH AVENUE WEST  
2ND FLOOR  
WESTFIELD, NJ 07090

EXAMINER

MCINTOSH III, TRAVIS C

ART UNIT PAPER NUMBER

1623

DATE MAILED 02 25 2003

5

Please find below and or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/745,226

Applicant(s)

HERRMANN ET AL.

Examiner

Traviss C McIntosh

Art Unit

1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on 02 December 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☐ Claim(s) 33-48, 50-56 and 58-70 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) 33-48, 50-56 and 58-70 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.

- 2) ☐ Notice of Draftsperson's Patent Drawing Review (Form 145)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_

- 4) ☐ Notice of Informal Patent Application (Form 150)
- 5) ☐ Other \_\_\_\_\_

***Detailed Action***

The Group and/or Art Unit of the U.S. Patent application SN 09/745,226 has changed. In order to expedite the correlation of papers with the application please direct all future correspondence to the Technology Center 1600, Art Unit 1623.

The following is in response to Amendment filed December 2, 2002.

The amendment advanced prosecution in response to the restriction requirement dated October 2, 2002.

Claims 1-32, 49, and 57 have been deleted.

Claims 33, 37, 39-41, 43-47, and 50-56 have been amended.

New claims 58-70 have been added.

Arguments are advanced regarding the restriction requirement which are addressed below.

***Election/Restrictions***

Applicant's election with traverse of Group II in Paper No. 4 is acknowledged. The traversal is on the ground(s) that the search would not be a serious burden because Groups III-VI are classified in the same class subclass.

Claims 50-56 of Groups III-VI, directed to the process of making or using the product, previously withdrawn from consideration as a result of a restriction requirement, are now subject to being rejoined. Process claims 50-56 are hereby rejoined and fully examined for patentability

Additionally, the species election, wherein applicant elected a lipid molecule having a sphingosine base as a backbone and a S-N=O nitric oxide group, has been withdrawn.

An action on the merits of claims 33-48, 50-56, and 58-70 is contained herein below.

### ***Information Disclosure Statement***

Acknowledgement is made of the Information Disclosure Statement filed March 14, 2001 and the references have been taken into consideration.

### ***Specification***

The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code on page 12, line 25. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 50-54 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating the various disorders, does not reasonably provide enablement for prevention. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope

Art Unit: 1623

A conclusion of lack of enablement means that, based on the evidence regarding each of the factors below, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation.

These factors include:

- (A) The breadth of the claims;
- (B) The nature of the invention;
- (C) The state of the prior art;
- (D) The level of one of ordinary skill;
- (E) The level of predictability in the art;
- (F) The amount of direction provided by the inventor;
- (G) The existence of working examples; and
- (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.

#### **The breadth of the claims**

Claims 50-54 are drawn to methods of treating and preventing various conditions, including atherosclerosis, myocardial infarction, restenosis, stroke, impotence, cancer, bacterial infection, impetigo, psoriasis, pruritis, and warts, comprising administering a drug delivery system comprising a lipid molecule derivatized to comprise a nitric oxide releasing group.

#### **The state of the prior art**

Nitric oxide is known to play a central role in diverse processes, such as host defense, cardiovascular regulation, signal transduction, neurotransmitting, and wound healing, as seen in US 5,519,020. Nitric Oxide is known to inhibit the aggregation of platelets, as seen in US 5,185,376. Nitric oxide is known to treat infectious disease caused by pathogenic microbes as seen in US 5,814,666. At present, there are no known agents capable of preventing all of the

Art Unit: 1623

prevention is high, and requires evidence commensurate in scope and correlative to prior art teachings.

**The level of predictability in the art**

The examiner acknowledges the probability and predictability that the active agent, which is nitric oxide, indeed has efficacy in treating the various disorders. However, the art is silent with regard to the predictability of the prevention of the various conditions, i.e. cancer. In fact, the art does not teach the prevention of cancer by any compounds or active agents. There is not seen to be sufficient data to substantiate the assertion that the various conditions may be prevented by the use of a nitric oxide releasing compound. One skilled in this art would not predict from the disclosure provided that these various conditions can be prevented in view of the data and examples provided, the silence of such predictability in the art and the lack of disclosures providing guidance or support for prevention of any disease or condition.

**The amount of direction provided by the inventor**

The instant specification is not seen to provide adequate guidance which would allow the skilled artisan to extrapolate from the disclosure and examples provided to enable the use the claimed method commensurate in scope with the instant claims. There is no data and there are no examples which adequately represent the scope of the claims as written. The examiner notes that there has not been provided sufficient instruction or sufficient methodological steps and procedures to support the alleged efficacy of the system as a preventive agent instantly asserted.

**The existence of working examples**

There are no examples in the instant application which are seen to provide support for

**The quantity of experimentation needed to make or use the invention based on the content of the disclosure**

Indeed, in view of the information set forth supra, the instant disclosure is not seen to be sufficient to enable the prevention of the various conditions without undue experimentation.

Reasonable guidance with respect to prevention, especially preventing cancer, relies on quantitative analysis from defined populations which have been successfully prescreened and are predisposed to particular types of the specific conditions. This type of data might be derived from a widespread genetic analysis, cancer clusters, or family histories. The essential element towards the validation of a preventive therapeutic is the ability to test the drug on subjects monitored in advance for the specific condition and to *link* those results with a subsequent histological confirmation of the presence or absence of the disease. This irrefutable link between antecedent drug treatment and subsequent knowledge of the prevention is the essence of verification of a valid preventive method.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 38 and 42 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim

Art Unit: 1623

explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 38 recites the broad recitation "the matrix is a biocompatible matrix", and the claim also recites "a biocompatible matrix selected from a stable polymer matrix and a biodegradable polymer matrix" which is the narrower statement of the range/limitation. Claim 42 recites the broad recitation "further comprising an...auxiliary therapeutic agent", and the claim also recites "an auxiliary therapeutic agent selected from agents having antineoplastic activity, agents having antiproliferative activity, and agents having ... both" which is the narrower statement of the range/limitation.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.



Art Unit: 1623

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- Determining the scope and contents of the prior art.
- Ascertaining the differences between the prior art and the claims at issue.
- Resolving the level of ordinary skill in the pertinent art.
- Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 33-48, 50-52, 56 and 58-70 are rejected under 35 U.S.C. 103(a) as being unpatentable over Stamler et al. (US Patent 5,770,645) in view of Garfield et al. (US Patent 5,698,738).

The claims of the instant invention are drawn to a drug delivery system comprising a medical article and a nitric oxide (NO) releasing compound. The NO releasing compound of the instant comprises a lipid molecule (any of phosphoglycerides (phosphatidylinositol or phosphatidylcholine), those having a sphingosine base as a backbone (N,N,N-trimethylsphingosine, a sphingolipid, or ganglioside), monoacylglycerides, diacylglycerides, glycosylacylglycerols, or sterols having the formula as in claim 33 of the instant (cholesterol)) comprising a S-nitroso, O-nitroso, or N-nitroso group. The medical article can be a bandage, patch, or intravascular medical device (balloon catheter, injection catheter, infusion catheter, a stent, a stent graft, or a distal protection device). The NO releasing compound may be in a polymer matrix, dissolved or dispersed in a solution, provided within a micelle or liposome, adsorbed on the tissue-contacting surface of the medical article, and additionally comprise an additional therapeutically effective agent. The instant application is additionally drawn to a

Art Unit: 1623

the patient. The drug delivery system may be administered topically, within the body, by implantation or an intravascular delivery device (balloon catheter, injection catheter, infusion catheter, a stent, a stent graft, or a distal protection device). Additionally claimed is a method of treating atherosclerosis, myocardial infarction, restenosis, peripheral vascular disease, stroke, impotence or septic shock in a patient comprising administering the drug delivery system to a patient.

Stamler et al. (Stamler) teach of polymers capable of delivering NO to a patient. NO is taught to inhibit platelet aggregation, reduce smooth muscle proliferation, reduce restenosis, thrombus formation, and to be an anti-inflammatory (column 1, lines 22-31). The polymer of Stamler has pendant S-nitroso and/or O-nitroso groups obtained by reacting a polythiolated polysaccharide with a nitrosylating agent or a nitrating agent under conditions suitable for nitrosylating or nitrating free thiol groups (column 2, lines 34-40). The polymers are coated on a medical device, which is then implanted into the patient, or for delivering NO to a bodily fluid, the bodily fluid is contacted with the coated medical device (column 2, lines 50-57). Suitable polymers which are to be nitrosylated for NO delivery include synthetic and natural polymers (polysaccharides or peptides) and can be hydrophobic or hydrophilic (column 3, lines 48-58). NO is connected to the polymers of Stamler via a linking group, which is preferably S, O, or N (column 4, lines 12-22). The NO delivering polymer of Stamler is prepared by reacting a polysaccharide having a pendant alcohol group with a thiolating reagent to form a thiolated polysaccharide, thereby reacting thiolated polysaccharide with nitrosylating agent to form a nitrosylated polysaccharide (column 6, lines 17-62). Stamler teach the polymer may be in a

polymer matrix (column 7, lines 37-45). Stamler additionally teach that coated stents may be examples of medical devices used for implantation (column 10, lines 5-62).

What is not taught by Stamler is to use lipids as the core molecule which will ultimately release NO.

Garfield et al. (Garfield) teach that decreased NO contributes to hypertension, atherosclerosis, and diabetes (column 1, lines 56-60). Garfield teaches that various N-nitroso-N-substituted hydroxylamines can be used as NO donors to treat these diseases. Additionally, Garfield teaches that suitable pharmaceutically acceptable carriers include vegetable oils, polyethylene glycol, and hydroxypropyl methylcellulose and that fats (vegetable oils) may be used as carriers utilizing microencapsulation (column 9, lines 4-32). These properties of fats render obvious the use of lipids in combination with NO. Garfield also teaches that the compounds capable of donating NO have a structure wherein the functional group is equal to that of claim 68, and more specifically claim 69 of the instant application (column 4, lines 30-47) wherein the R group is a steroid, or a biologically active moiety designed to target the NO releasing agent to a specific organ or tissue (column 5, lines 18-25).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to combine the teachings of Stamler and Garfield to obtain a drug delivery system which comprises a medical article and a lipid molecule comprising a N-nitroso, O-nitroso, or S-nitroso functional group which is capable of delivering NO to a patient. Garfield teaches to attach a NO donating group (as in claims 68 and 69 of the instant) to a steroid, which is a lipid. One of ordinary skill in the art would have a reasonable expectation of success in using other

Art Unit: 1623

-N-N=O moiety which provides the function of releasing the therapeutically effective NO group.

One would be motivated to use lipids as the R group because lipids are known to form liposomes, wherein an additional active agent could be entrapped in the liposome which would then provide an additional therapeutic activity.

Claims 33-48, 50-54, 56 and 58-70 rejected under 35 U.S.C. 103(a) as being unpatentable over Stamler and Garfield as applied to claims 33-48, 50-52, 56 and 58-70 above, and further in view of Green et al. (Green) (US Patent 5,814,666).

The claims of the instant application are drawn to the drug delivery system as set forth supra, and additionally to a method of treating cancer or bacterial infections, or warts (a papova-type viral infection).

Stamler and Garfield teach the drug delivery system as set forth supra, what is not taught is to use the drug delivery system to treat cancer or bacterial infections or warts.

Green teaches to use liposomes containing nitric oxide donors to treat macrophage-based diseases caused by viruses, bacteria, fungi, and parasites (column 4, lines 63-65).

It would have been obvious to one of ordinary skill in the art at the time of the invention to use the drug delivery system as taught by Stamler and Garfield to treat the diseases as taught by Green because Green teaches the disease is treated by a nitric oxide donating complex. One would be motivated to use the system of Stamler and Garfield because the lipids would form into a liposome as indicated by Green, and comprise the nitric oxide releasing group (N-, O-, or S-nitroso group) in the complex.

Art Unit: 1623

Claims 33-48, 50-52, 55, 56 and 58-70 rejected under 35 U.S.C. 103(a) as being unpatentable over Stamler and Garfield as applied to claims 33-48, 50-52, 56 and 58-70 above, and further in view of Smith et al. (Smith) (US Patent 5,519,020).

The claims of the instant application are drawn to the drug delivery system as set forth supra, and additionally to a method of promoting wound healing in a patient.

Stamler and Garfield teach the drug delivery system as set forth supra, what is not taught is to use the drug delivery system as a method of promoting wound healing in a patient.

Smith teaches to use a controlled release NO releasing compound to promote wound healing in a patient (column 3, lines 55-57).

It would have been obvious to one of ordinary skill in the art at the time of the invention to use the drug delivery system as taught by Stamler and Garfield to promote wound healing as taught by Smith because Smith teaches that wound healing is accelerated by a nitric oxide. One would be motivated to use the system of Stamler and Garfield because the lipids would form into a liposome and have the capability of comprising an additional active agent, as well as comprising the nitric oxide releasing group (N-, O-, or S-nitroso group) in the complex.

The references listed on the Examiners form PTO-892 which were not cited in this Office Action are drawn to the general state of the art of the instant application.

Art Unit: 1623

***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Traviss McIntosh whose telephone number is 703-308-9479. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 703-308-4624. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

A handwritten signature in black ink, appearing to read "James O. Wilson", with a long horizontal line extending to the right.

James O. Wilson  
Supervisory Patent Examiner  
Art Unit 1623

Traviss C. McIntosh  
February 24, 2003